Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Cidara Therapeutics, Inc. CDTX
$1.20
+$0.02 (1.69%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
102628272.00000000
-
week52high
2.10
-
week52low
0.40
-
Revenue
64288000
-
P/E TTM
-3
-
Beta
1.33529400
-
EPS
-0.41000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:13
Описание компании
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 12 мая 2022 г. |
| WBB Securities | Strong Buy | Buy | 22 сент 2021 г. |
| Aegis Capital | Buy | Buy | 22 сент 2021 г. |
| Aegis Capital | Buy | 04 мар 2021 г. | |
| Citigroup | Buy | Buy | 26 авг 2020 г. |
| HC Wainwright & Co. | Buy | Buy | 25 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Tari Leslie | D | 1484 | 11814 | 12 янв 2023 г. |
| Shah Preetam | D | 150789 | 15642 | 19 сент 2022 г. |
| Shah Preetam | D | 0 | 50000 | 15 сент 2022 г. |
| Shah Preetam | A | 166431 | 50000 | 15 сент 2022 г. |
| Sandison Taylor | D | 291753 | 18478 | 12 сент 2022 г. |
| Tari Leslie | D | 193741 | 18159 | 12 сент 2022 г. |
| Daruwala Paul | D | 221099 | 16199 | 12 сент 2022 г. |
| BURGESS DANIEL D | A | 28000 | 28000 | 22 июн 2022 г. |
| Franson Timothy R | A | 28000 | 28000 | 22 июн 2022 г. |
| Bassler Bonnie L | A | 28000 | 28000 | 22 июн 2022 г. |
Новостная лента
Top Penny Stocks To Buy Now? 10 To Watch Under $5
PennyStocks
13 апр 2023 г. в 11:27
10 Penny stocks under $5 to watch right now The post Top Penny Stocks To Buy Now? 10 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Cidara Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire
31 мар 2023 г. в 08:00
SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, is scheduled to participate in the following upcoming investor conferences.
7 Top Penny Stocks Under $5; Time To Buy Now?
PennyStocks
29 мар 2023 г. в 11:28
Penny stocks to watch before next week. The post 7 Top Penny Stocks Under $5; Time To Buy Now?
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
23 мар 2023 г. в 09:54
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -1,800% and 45.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Is Cidara Therapeutics (CDTX) Stock Down 12% Today?
InvestorPlace
23 мар 2023 г. в 09:16
Cidara Therapeutics (NASDAQ: CDTX ) stock is falling on Thursday despite the immunotherapy company getting positive news from the FDA. The big FDA news is the approval of rezafungin as a treatment for “candidemia and invasive candidiasis in adult patients with limited or no alternative treatment options.